诺泰生物(688076) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was ¥113,938,273.65, a decrease of 19.12% compared to the same period last year[8] - Net profit attributable to shareholders for Q3 2022 was ¥18,361,297.20, down 16.02% year-over-year[8] - Net profit excluding non-recurring gains and losses for Q3 2022 was ¥578,020.36, a significant decline of 96.85% compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 was ¥382,238,680.01, a decrease of 15% compared to ¥449,877,162.41 in the same period of 2021[32] - Net profit for the third quarter of 2022 was ¥48,653,233.84, down 30% from ¥69,525,337.97 in the third quarter of 2021[38] - Earnings per share for the third quarter of 2022 were ¥0.25, compared to ¥0.40 in the same quarter of 2021[40] Research and Development - R&D investment for Q3 2022 totaled ¥20,523,354.60, an increase of 49.04% year-over-year, representing 18.01% of revenue[12] - Research and development expenses for the third quarter of 2022 were ¥49,547,134.58, an increase from ¥44,422,127.37 in the previous year[35] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥2,376,710,654.67, an increase of 11.74% from the end of the previous year[12] - The company's total assets amounted to approximately ¥2.38 billion, an increase from ¥2.13 billion at the end of 2021, reflecting a growth of about 11.7%[30] - The company's total liabilities increased to ¥526,122,650.75 in 2022 from ¥318,137,446.34 in 2021[32] - Total current liabilities rose to approximately ¥483.28 million, up from ¥275.40 million, reflecting an increase of about 75.4% year-over-year[30] - The company's non-current assets totaled approximately ¥1.36 billion, an increase from ¥1.02 billion, indicating a growth of about 33.1%[30] Cash Flow - Cash flow from operating activities for the year-to-date was negative at -¥15,425,321.93, a decline of 111.70% compared to the previous year[12] - The net cash flow from operating activities was -$15,425,321.93, a significant decrease compared to $131,827,280.03 in the previous period[42] - Cash inflow from operating activities for the first three quarters of 2022 was ¥409,786,781.52, down from ¥554,516,533.82 in the same period of 2021[41] - The cash outflow for operating activities was $425,212,103.45, slightly higher than $422,689,253.79 in the previous period[42] Investments and Financing - The company reported a significant increase in investment income to ¥19,813,526.18 in the third quarter of 2022, compared to ¥1,790,339.17 in the same quarter of 2021[35] - Cash inflow from investment activities totaled $633,880,182.43, slightly down from $638,790,339.17 year-over-year[42] - The net cash flow from investment activities was -$349,190,220.68, worsening from -$202,083,694.94 in the prior period[42] - Cash inflow from financing activities was $372,140,000.00, a decrease from $884,930,398.14 in the previous year[42] - The net cash flow from financing activities was $218,839,953.16, down from $521,003,577.78 year-over-year[42] Other Notable Points - The company reported an increase in management and sales expenses, contributing to the decline in net profit[17] - The company's cash and cash equivalents decreased to approximately ¥428.81 million from ¥591.88 million, representing a decline of about 27.5% year-over-year[27] - Inventory levels increased significantly to approximately ¥330.17 million, up from ¥250.82 million, indicating a rise of approximately 31.7% compared to the previous year[27] - The company's short-term borrowings surged to approximately ¥298.36 million, compared to ¥77.27 million at the end of 2021, marking an increase of about 286.5%[30] - The company has no significant updates regarding new products or technologies in the current report period[24] - There are no notable mergers or acquisitions reported during the current period[24] - The company has not provided specific future guidance or outlook in the current report[24]